Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin for Chemotherapy-induced Cardiotoxicity in HER2+ Breast Cancer
NCT05338723Phase 3Completed
- Sponsor
- Tanta University
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rosuvastatin in chemotherapy-induced cardiotoxicity (CIC), sponsored by Tanta University. Started Sep 2020; status: completed.
02
Drugs
rosuvastatin
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)
Beyond the preview
Go deeper on NCT05338723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338723.